Stroke prevention in hospitalized patients with atrial fibrillation: A population-based study

Canadian Journal of Clinical Pharmacology

Volumn 10, Issue 4, 2003, Pages 197-201

  Nagpal, Seema ^a,b   Anderson, David ^b,c   Putnam, Wayne ^b   Flowerdew, Gordon ^b   Gardner, Martin ^b   Cox, Jafna ^b  

^a Centre for Chronic Disease Prevention and Control   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

^c QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Access to drugs; Cost effectiveness evaluation; Drug benefit plans; Drug listing process; Drug reimbursement decision making

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; WARFARIN;

ANTICOAGULATION; ARTICLE; BLEEDING; CANADA; COHORT ANALYSIS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DEMOGRAPHY; DIABETES MELLITUS; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE SYSTEM; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART VALVE PROSTHESIS; HOSPITALIZATION; HUMAN; HYPERLIPIDEMIA; INCIDENCE; MEDICAL DOCUMENTATION; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OUTCOMES RESEARCH; POPULATION RESEARCH; PROSPECTIVE STUDY; REIMBURSEMENT; RISK FACTOR; STROKE; TRANSIENT ISCHEMIC ATTACK;

EID: 0842278744     PISSN: 1198581X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Arch Intern Med 1995;155:469-73.
2. Krahn AD, Manfreda J, Tate R, Mathewson FAL, Cuddy TE. The natural history of atrial fibrillation: Incidence, risk factors, and prognosis in the Manitoba follow-up study. Am J Med 1995;98:476-84.
3. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation. N Engl J Med 1982;306:1018-22.
4. Laupacis A, Cuddy TE. Prognosis of individuals with atrial fibrillation. Can J Cardiol 1996;12(Suppl A):14A-6A.
5. Connolly SJ, Turpie AGG. Antithrombotic therapy in atrial fibrillation. Can J Cardiol 1996;12:17A-20A.
6. Hirsh J, Dalen JE, Deykin D, Poller L, Bussey H. Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1995;108:231S-46S.
7. Hirsh J, Dalen JE, Fuster V, Harker LB, Patrono C, Roth G. Aspirin and other platelet-active drugs. Chest 1995;108:247S-57S.
8. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of anti-thrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-57.
9. Stafford RS, Singer DE. National patterns of warfarin use in atrial fibrillation. Arch Intern Med 1996;156:2537-41.
10. Albers GW, Yim JM, Belew KM, et al. Status of antithrombotic therapy for patients with atrial fibrillation in university hospitals. Arch Intern Med 1996;156:2311-6.
11. Brass LM, Krumholz HM, Scinto JM, Radford M. Warfarin use among patients with atrial fibrillation. Stroke 1997;28:2382-9.
12. Whittle J, Wickenheiser L, Venditti LN. Is warfarin underused in the treatment of elderly persons with atrial fibrillation? Arch Intern Med 1997;157:441-5.
13. Gottlieb LK, Salem-Schatz S. Anticoagulation in atrial fibrillation. Does efficacy in clinical trials translate into effectiveness in practice? Arch Intern Med 1994;154:1945-53.
14. Munschauer FE, Priore RL, Hens M, Castilone A. Thromboembolism prophylaxis in chronic atrial fibrillation. Practice patterns in community and tertiary-care hospitals. Stroke 1997;28:72-6.
15. Antani MR, Beyth RJ, Covinsky KE, et al. Failure to prescribe warfarin to patients with nonrheumatic atrial fibrillation. J Gen Intern Med 1996;11:713-20.
16. Mead GE, Murray H, McCollum CN, O'Neill PA. How do general practitioners manage patients at risk from stroke? Br J Clin Pract 1996;50:426-30.
17. O'Connell JE, Gray CS. Atrial fibrillation and stroke prevention in the community. Age and Ageing 1996;25:307-9.
18. Llop R, Ferrer A, Agusti A, Vidal X, Arnau JM, Laporte J-R. From clinical trials to clinical practice: Oral anticoagulation among patients with non-rheumatic, atrial fibrillation. Eur J Clin Pharmacol 1997;53:1-5.
19. Cox JL, on behalf of the ICONS Investigators. Optimizing disease management at a health care system level: The rationale and methods of the Improving Cardiovascular Outcomes in Nova Scotia (ICONS) Study. Can J Cardiol 1999;15:787-96.
20. Gurwitz JH, Monette J, Rochon PA, Eckler MA, Avorn J. Atrial Fibrillation and stroke prevention with warfarin in the long-term care setting. Arch Intern Med 1997;157:978-84.
21. Lawson F, McAlister F, Ackman M, Ikuta R, Montague T. The utilization of antithrombotic prophylaxis for atrial fibrillation in a geriatric rehabilitation hospital. J Am Geriatr Soc 1996;44:708-11.
22. The Clinical Quality Improvement network (CQIN) Investigators. Thromboembolic prophylaxis in 3575 hospitalized patients with atrial fibrillation. Can J Cardiol 1998;14:695-702.
23. Cannegieter SC, Rosendaal FR, Wintzen AR, Van Der Meer FJM, Vandenbroucke JP, Briet E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995;333:11-7.
24. Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care. Arch Intern Med 1998;158:1641-7.
25. Bussey HI, Respond RM, Quandt CM, Clark GM. The safety and effectiveness of long-term warfarin therapy in an anticoagulation clinic. Pharmacotherapy 1989;9:214-9.
26. Devereaux PJ, Anderson DR, Gardner MJ, et al. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: Observational study. BMJ 2001;323:1218-22.